Biogen Idec’s ALS drug Failed Final Clinical Trial

.

Biogen Idec’s ALS drug Failed Final Clinical Trial

As per reports, it has been recently revealed that Biogen Idec was unable to get through the last clinical trial of its ALS drug. Researchers have acknowledged the loss by saying that it was not only shocking but discouraging as well.

Dr. Robert Brown, who is an ALS researcher, was of the view that they have worked hard on the drug, but they failed a crucial test. However, this does not mean that no more research will take as the disease needs an effective treatment.

While talking about the last and final clinical trial, which could not attain success, Brown said that they had enrolled 943 people, who were suffering from amyotrophic lateral sclerosis. They were enrolled to test the efficacy of their once-promising dexpramipexole drug.

After carrying out the study, Brown said that they did not find any sort of benefit from the drug. And, then only, they decided to halt the programme. "While these results were not what we expected, we hope this data will provide a foundation for future ALS research", said Dr. Douglas Kerr, who is the director of neurodegeneration clinical research at Biogen.

The failure does not mark an end to the research, said Kerr, as they still have been working on it.

 


Latest News

New Zealand Once Again Raises Its Interest Rate Now to 3.5 Percent
UN Human Development Report Points at Inequality for Slow Progress
Facebook Perched to Reach a Record High After Heavy Quarterly Gains
July HSBC Survey Reveal China PMI at All Time High in 18-months
A Woman for the First Time to Join Board of American Apparel
Glaciers Melt near Lahaul, Spiti Make Officials Warn about Flooding
A.H. Belo Corp. Will Sell Providence Journal Newspaper to New Media
Comcast’s Second Quarter Earnings Increase as a Result of Added Internet Custome
Sugar tax Make it to San Francisco Ballot in a 6-4 Vote
GasBuddy.com: Gas prices in the US dropped to $3.57 per gallon in the last week
Customers Order For More Burritos Though Chipotle Raises Prices
Netflix Surpasses 50 Million Subscriptions as Its Second Quarter Earnings Get a